Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114871 | 1.00 | CYP3A4 (0.31) | CYP3A4AVPR1BTP53 | |
| SCHEMBL20101201 | 0.93 | TP53 (0.30) | CYP3A4TP53 | |
| SCHEMBL31114894 | 0.93 | TP53 (0.30) | CYP3A4TP53 | |
| SCHEMBL22506430 | 0.93 | CYP3A4 (0.38) | CYP3A4AVPR1B | |
| SCHEMBL20101194 | 0.93 | CYP3A4 (0.38) | CYP3A4AVPR1B | |
| SCHEMBL31114920 | 0.92 | TP53 (0.30) | TP53 | |
| SCHEMBL20101203 | 0.92 | TP53 (0.30) | TP53 | |
| SCHEMBL20030665 | 0.91 | NPSR1 (0.33) | CYP3A4TP53 | |
| SCHEMBL23100103 | 0.90 | TP53 (0.31) | CYP3A4TP53 | |
| SCHEMBL20101151 | 0.88 | PDE2A (0.30) | CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP3A4 182/4885AVPR1B 2628/4885TP53 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.